{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T09:55:31Z","timestamp":1785578131891,"version":"3.56.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,19]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Imatinib is a standard treatment for Philadelphia (Ph) chromosome-positive chronic myeloid leukemia (CML), but its efficacy in rare <jats:italic toggle=\"yes\">BCR::ABL<\/jats:italic> variants is underexplored.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 67-year-old woman was admitted to the Second Affiliated Hospital of Xi\u2019an Jiaotong University in March 2022 due to elevated white blood cells.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>Karyotype analysis revealed clonal abnormalities involving the variant t(9;22) and positive results for atypical <jats:italic toggle=\"yes\">BCR::ABL<\/jats:italic> variants (e14a3 and e13a3). The clinical diagnosis was CML, chronic phase, Ph+, with rare <jats:italic toggle=\"yes\">BCR::ABL<\/jats:italic>-e13a3- and <jats:italic toggle=\"yes\">BCR::ABL<\/jats:italic>-e14a3-positive findings.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Intervention:<\/jats:title>\n            <jats:p>The patient was administered daily imatinib mesylate (400\u2009mg).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>After 4 weeks, a swift molecular response was observed: <jats:italic toggle=\"yes\">BCR::ABL<\/jats:italic>-e13a3 transcript level at 2.82\u2005\u00d7\u200510<jats:sup>\u22121<\/jats:sup> (28.24%), and <jats:italic toggle=\"yes\">BCR::ABL<\/jats:italic>-e14a3 transcript level at 4.68\u2005\u00d7\u200510<jats:sup>\u22121<\/jats:sup> (46.76%). Within 3 months, a complete cytogenetic response was achieved, with a Ph chromosome ratio of 0. Early molecular response was evident as <jats:italic toggle=\"yes\">BCR::ABL<\/jats:italic>-e13a3 transcript level reached 5.11\u2005\u00d7\u200510<jats:sup>\u22123<\/jats:sup> (0.51%), and <jats:italic toggle=\"yes\">BCR::ABL<\/jats:italic>-e14a3 transcript level at 6.26\u2005\u00d7\u200510<jats:sup>\u22123<\/jats:sup> (0.63%). The imatinib mesylate treatment continued without significant toxicity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>This case emphasizes the potential effectiveness of imatinib mesylate in managing rare <jats:italic toggle=\"yes\">BCR::ABL<\/jats:italic> fusion gene variants of CML. Screening for these atypical variants is advised for suspected CML patients who test negative for common <jats:italic toggle=\"yes\">BCR::ABL<\/jats:italic> fusion gene variants. The presented case underscores the positive outcomes achieved with imatinib treatment for a patient with rare <jats:italic toggle=\"yes\">BCR::ABL<\/jats:italic> variants, contributing valuable insights for the management of similar cases. Screening for unusual fusion gene variants should be a consideration in CML diagnosis for comprehensive treatment strategies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000036728","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T21:03:24Z","timestamp":1705698204000},"page":"e36728","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Chronic myeloid leukemia with two rare fusion gene transcripts of atypical BCR::ABL: A case report and literature review"],"prefix":"10.1097","volume":"103","author":[{"given":"Yuxin","family":"Li","sequence":"first","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, Shaanxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, Shaanxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, Shaanxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheping","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, Shaanxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, Shaanxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longjin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, Shaanxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7696-4728","authenticated-orcid":false,"given":"Xiaorong","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, Shaanxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"suppl_4","key":"R2-20250505","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","article-title":"Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.","volume":"28","author":"Hochhaus","year":"2017","journal-title":"Ann Oncol"},{"key":"R3-20250505","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"4841 Pt 1","key":"R4-20250505","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1126\/science.3422516","article-title":"Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL).","volume":"239","author":"Clark","year":"1988","journal-title":"Science"},{"key":"R5-20250505","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia.","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"key":"R6-20250505","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.3892\/mmr.2016.4826","article-title":"Complete cytogenetic response to Nilotinib in a chronic myeloid leukemia case with a rare e13a3(b2a3) BCR-ABL fusion transcript: a case report.","volume":"13","author":"Liu","year":"2016","journal-title":"Mol Med Rep"},{"key":"R7-20250505","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/s41375-018-0341-4","article-title":"The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia An international overview.","volume":"33","author":"Baccarani","year":"2019","journal-title":"Leukemia"},{"key":"R8-20250505","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2165\/00003495-200767020-00010","article-title":"Imatinib: a review of its use in chronic myeloid leukaemia.","volume":"67","author":"Moen","year":"2007","journal-title":"Drugs"},{"key":"R9-20250505","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1182\/blood-2015-10-674242","article-title":"Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors.","volume":"127","author":"Jain","year":"2016","journal-title":"Blood"},{"key":"R10-20250505","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.18632\/oncotarget.27652","article-title":"Influence of major BCR-ABL1 transcript subtype on outcome in patients with chronic myeloid leukemia in chronic phase treated frontline with nilotinib.","volume":"11","author":"Genthon","year":"2020","journal-title":"Oncotarget"},{"key":"R11-20250505","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/ajh.10456","article-title":"Chronic myeloid leukemia with an e13a3 BCR-ABL fusion: benign course responsive to imatinib with an RT-PCR advisory.","volume":"75","author":"Snyder","year":"2004","journal-title":"Am J Hematol"},{"key":"R12-20250505","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1084\/jem.189.8.1229","article-title":"Signal transducer and activator of transcription (STAT)5 activation by BCR\/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR\/ABL and is required for leukemogenesis.","volume":"189","author":"Nieborowska-Skorska","year":"1999","journal-title":"J Exp Med"},{"key":"R13-20250505","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.leukres.2005.04.001","article-title":"CML patient with rare b 2 a 3 (e 13 a 3) variant of BCR-ABL transcript: complete molecular response to imatinib.","volume":"29","author":"Moravcova","year":"2005","journal-title":"Leuk Res"},{"key":"R14-20250505","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2353\/jmoldx.2009.090008","article-title":"A rare e14a3 (b3a3) BCR-ABL fusion transcript in chronic myeloid leukemia: diagnostic challenges in clinical laboratory practice.","volume":"11","author":"Jinawath","year":"2009","journal-title":"J Mol Diagn"},{"key":"R15-20250505","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.3109\/10428194.2015.1037751","article-title":"Chronic myeloid leukemia with e14a3 BCR-ABL transcript: analysis of characteristics and prognostic significance.","volume":"56","author":"Gui","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"R16-20250505","first-page":"457","article-title":"bcr-abl mRNA lacking abl exon a2 detected by polymerase chain reaction in a chronic myelogeneous leukemia patient.","volume":"5","author":"van der Plas","year":"1991","journal-title":"Leukemia"},{"key":"R17-20250505","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/ajh.10429","article-title":"Chronic myelogenous leukemia with e13a3 (b2a3) type of BCR-ABL transcript having a DNA breakpoint between ABL exons a2 and a3.","volume":"74","author":"Liu","year":"2003","journal-title":"Am J Hematol"},{"key":"R18-20250505","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/bjh.15453","article-title":"Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre.","volume":"182","author":"Qin","year":"2018","journal-title":"Br J Haematol"},{"key":"R19-20250505","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1080\/10428194.2019.1607329","article-title":"Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts.","volume":"60","author":"Xue","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"R20-20250505","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1007\/s00432-021-03569-8","article-title":"Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network.","volume":"147","author":"Schafer","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"R21-20250505","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.leukres.2017.05.009","article-title":"A rare e13a3 (b2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic myeloid leukemia: the challenges in diagnosis and monitoring minimal residual disease (MRD).","volume":"59","author":"Duan","year":"2017","journal-title":"Leuk Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000036728","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T20:04:33Z","timestamp":1746475473000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000036728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,19]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000036728","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,19]]}}}